| $350M | ||
| $172M | ||
| $115M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $ | – | |
Sells | $ | – |
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Over the last 12 months, insiders at Nuvalent, Inc. have bought $undefined and sold $undefined worth of Nuvalent, Inc. stock.
On average, over the past 5 years, insiders at Nuvalent, Inc. have bought $75.32M and sold $103.81M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 650,000 shares for transaction amount of $21.77M was made by Flynn James E (director) on 2022‑11‑03.
| Increased Positions | 163 | +101.24% | 12M | +16.32% |
| Decreased Positions | 66 | -40.99% | 5M | -6.54% |
| New Positions | 59 | New | 3M | New |
| Sold Out Positions | 17 | Sold Out | 240,686 | Sold Out |
| Total Postitions | 258 | +60.25% | 80M | +9.78% |
| Deerfield Management Company, L.P. | $1.81M | 26.85% | 17.99M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $1.01M | 14.95% | 10.01M | +44,391 | +0.45% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $531,370.00 | 7.87% | 5.27M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $464,369.00 | 6.87% | 4.61M | +80,883 | +1.79% | 2025-09-30 |
| Blackrock, Inc. | $412,012.00 | 6.1% | 4.09M | +39,539 | +0.98% | 2025-09-30 |
| Wellington Management Group Llp | $232,019.00 | 3.43% | 2.3M | +724,491 | +45.96% | 2025-09-30 |
| Janus Henderson Group Plc | $220,706.00 | 3.27% | 2.19M | +406,093 | +22.78% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $182,563.00 | 2.7% | 1.81M | +15,047 | +0.84% | 2025-09-30 |
| Jpmorgan Chase & Co | $168,807.00 | 2.5% | 1.67M | +476,822 | +39.83% | 2025-09-30 |
| State Street Corp | $158,797.00 | 2.35% | 1.57M | +84,468 | +5.67% | 2025-09-30 |